Inhibition of NF-κB Activity Enhances TRAIL Mediated Apoptosis in Breast Cancer Cell Lines
- 1 November 2000
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 64 (2) , 211-219
- https://doi.org/10.1023/a:1006458407515
Abstract
Most breast cancer cell lines are resistant to TNF-related apoptosis inducing ligand (TRAIL) induced apoptosis. In sensitive breast cancer cell lines TRAIL rapidly induces the cleavage and activation of caspases leading to the subsequent cleavage of downstream caspase substrates. In contrast, there is no caspase activation in the resistant cell lines. The transcription factor NF-κB can inhibit apoptosis induced by a variety of stimuli including activation of death receptors. We investigated whether NF-κB contributes to the resistance of breast cancer cells to TRAIL induced apoptosis. All of the resistant breast cancer cell lines expressed NF-κB and had detectable NF-κB activity in nuclear extracts prior to treatment with TRAIL. Upon TRAIL treatment, a significant increase in NF-κB activity was seen in most of the cell lines. To directly test if NF-κB activity contributes to the resistance of these cell lines to TRAIL, we transiently transfected the resistant cell lines with an inhibitor of NF-κB (IκBΔN) and measured TRAIL induced apoptosis in control and transfected cells. All of the resistant cell lines tested showed an increase in TRAIL induced apoptosis when transfected with the IκBΔN. These results demonstrate that TRAIL resistant breast cancer cells fail to rapidly activate the apoptotic machinery but they do activate NF-κB. Inhibition of NF-κB activity increases the sensitivity to TRAIL mediated apoptosis in resistant cells. These results suggest that agents which inhibit NF-κB should increase the clinical efficacy of TRAIL in breast cancer cells.Keywords
This publication has 32 references indexed in Scilit:
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999
- Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent MannerThe Journal of cell biology, 1999
- TRAIL/Apo-2-ligand-induced apoptosis in human T cellsEuropean Journal of Immunology, 1998
- The Novel Receptor TRAIL-R4 Induces NF-κB and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death DomainImmunity, 1997
- An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAILScience, 1997
- An Essential Role for NF-κB in Preventing TNF-α-Induced Cell DeathScience, 1996
- Identification and characterization of a new member of the TNF family that induces apoptosisImmunity, 1995
- The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and deathCell, 1994
- Lethal effect of the anti-Fas antibody in miceNature, 1993